Stockholders to Receive $27.25 Per Share in Cash
Apr. 5, 2011 (Business Wire) -- CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today announced that it has completed its previously announced sale to FCB I Holdings Inc. ("FCB") for $27.25 per share in cash. Stockholders approved the merger agreement between CPEX and FCB at a special meeting of stockholders held on March 24, 2011.
The transaction price represents a 142% premium over the price of CPEX shares on January 7, 2010, the day prior to the date a third party publicly stated its intention to make an unsolicited offer for CPEX, and a premium of approximately 12% over the 60-trading day average closing price of CPEX's shares on the date prior to the announcement of the merger with FCB.
"We are pleased to complete this value maximizing transaction and appreciate the support of our stockholders, employees and partners since the Company's inception in 2008," said John A. Sedor, CPEX President and Chief Executive Officer.
As a result of the transaction, CPEX's stock ceased trading on the NASDAQ at close of market today.
RBC Capital Markets, LLC and Goodwin Procter LLP served as financial and legal advisors, respectively, to CPEX.
About CPEX Pharmaceuticals, Inc.
CPEX Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, licensing and commercialization of pharmaceutical products utilizing CPEX's validated drug delivery platform technology. CPEX has U.S. and international patents and other proprietary rights to technology that facilitates the absorption of drugs. CPEX has licensed applications of its proprietary CPE-215® drug delivery technology to Auxilium Pharmaceuticals, Inc. which launched Testim, a topical testosterone gel, in 2003. CPEX maintains its headquarters in Exeter, NH. For more information about CPEX, please visit www.cpexpharm.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Certain items in this document may constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those indicated in such forward-looking statements, including, but not limited to: the proposed transaction with FCB; the performance of CPEX; the benefits of the proposed transaction with FCB and such other risks and uncertainties as are detailed in CPEX's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on February 4, 2011, in CPEX's Annual Report on Form 10-K filed with the SEC on March 29, 2010, and in the other reports that CPEX periodically files with the SEC. Copies of CPEX's filings with the SEC may be obtained by the methods previously disclosed. CPEX cautions investors not to place undue reliance on the forward-looking statements contained in this document or other filings with the SEC.
The statements in this document reflect the expectations and beliefs of CPEX's management only as of the date of this document and subsequent events and developments may cause these expectations and beliefs to change. CPEX undertakes no obligation to update or revise these statements, except as may be required by law. These forward-looking statements do not reflect the potential impact of any future dispositions or strategic transactions, including the proposed transaction with FCB, that may be undertaken. These forward-looking statements should not be relied upon as representing CPEX's views as of any date after the date of this document.
Investor Contacts:
CPEX Pharmaceuticals, Inc.
Bob Hebert,
603-658-6100
Chief Financial Officer
or
MacKenzie Partners
Amy
Bilbija, 212-929-5500
or
Press Contacts:
Sard Verbinnen &
Co
Andrew Cole/Chris Kittredge, 212-687-8080